Adimab
Adimab LLC specializes in the discovery, development, and optimization of human monoclonal and bispecific antibodies, catering to the pharmaceutical biotechnology sector. Founded in 2007 and located in Lebanon, New Hampshire, Adimab employs an integrated antibody discovery platform that accelerates the process from antigen to purified human immunoglobulins. The company focuses on producing a diverse range of therapeutic antibodies, such as IgG and CD3-based bispecific antibodies, ensuring high standards for affinity, epitope coverage, and species cross-reactivity. By leveraging its yeast-based technology, Adimab enhances the quality of therapeutic leads, facilitating the creation of innovative treatments for cancer, autoimmune disorders, and infectious diseases. The company also provides partners with various technology access arrangements to expand their biologics pipelines efficiently.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.